Cue Biopharma (NASDAQ:CUE) Raised to “Strong-Buy” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Cue Biopharma (NASDAQ:CUE) from a hold rating to a strong-buy rating in a report issued on Friday, Zacks.com reports. They currently have $10.00 price target on the stock.

According to Zacks, “Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts. “

Other equities analysts have also issued reports about the stock. Robert W. Baird assumed coverage on shares of Cue Biopharma in a research note on Thursday, July 25th. They issued an outperform rating and a $13.00 target price for the company. ValuEngine lowered shares of Cue Biopharma from a hold rating to a sell rating in a research note on Wednesday, November 13th.

Shares of CUE stock traded up $0.28 on Friday, hitting $9.08. The stock had a trading volume of 177,800 shares, compared to its average volume of 83,483. The firm has a market cap of $206.72 million, a P/E ratio of -4.68 and a beta of 1.21. The company has a current ratio of 3.17, a quick ratio of 3.17 and a debt-to-equity ratio of 0.10. Cue Biopharma has a twelve month low of $4.16 and a twelve month high of $9.94. The company has a fifty day moving average price of $8.11 and a two-hundred day moving average price of $8.05.

A number of hedge funds and other institutional investors have recently made changes to their positions in CUE. Russell Investments Group Ltd. acquired a new position in Cue Biopharma in the 3rd quarter worth $67,000. Strs Ohio boosted its stake in Cue Biopharma by 500.0% in the 2nd quarter. Strs Ohio now owns 15,000 shares of the company’s stock worth $134,000 after purchasing an additional 12,500 shares during the period. Sigma Planning Corp boosted its stake in Cue Biopharma by 13.6% in the 2nd quarter. Sigma Planning Corp now owns 47,805 shares of the company’s stock worth $430,000 after purchasing an additional 5,706 shares during the period. Rock Creek Group LP acquired a new position in Cue Biopharma in the 2nd quarter worth $447,000. Finally, Northern Trust Corp boosted its stake in Cue Biopharma by 2.0% in the 2nd quarter. Northern Trust Corp now owns 204,555 shares of the company’s stock worth $1,839,000 after purchasing an additional 3,970 shares during the period. 20.00% of the stock is owned by hedge funds and other institutional investors.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.

Recommended Story: Day Trading – Risk Worth the Reward?

Get a free copy of the Zacks research report on Cue Biopharma (CUE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brokerages Expect Heico Corp  Will Announce Earnings of $0.57 Per Share
Brokerages Expect Heico Corp Will Announce Earnings of $0.57 Per Share
Huntington Ingalls Industries Inc  Expected to Announce Earnings of $4.32 Per Share
Huntington Ingalls Industries Inc Expected to Announce Earnings of $4.32 Per Share
Slack  Posts  Earnings Results, Beats Estimates By $0.07 EPS
Slack Posts Earnings Results, Beats Estimates By $0.07 EPS
Korn Ferry  Posts  Earnings Results, Beats Expectations By $0.01 EPS
Korn Ferry Posts Earnings Results, Beats Expectations By $0.01 EPS
Stemline Therapeutics Inc  Director Purchases $10,290.00 in Stock
Stemline Therapeutics Inc Director Purchases $10,290.00 in Stock
Zacks: Analysts Anticipate BEST Inc.  to Post $0.04 EPS
Zacks: Analysts Anticipate BEST Inc. to Post $0.04 EPS


 
© 2006-2019 Zolmax.